Article
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Journal for immunotherapy of cancer - 1 Jun 2020
Martens Anne W J, Janssen Susanne R, Derks Ingrid A M, Adams Iii Homer C, Izhak Liat, van Kampen Roel, Tonino Sanne H, Eldering Eric, van der Windt Gerritje J W, Kater Arnon P
Abstract excerpt
BACKGROUND: Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T cell activation despite described T cell dysfunction in chronic lymphocytic leukemia (CLL), and are able to effectively target high-risk or venetoclax-resistant samples, is currently unknown. METHODS: CD19+ cell lines or primary (high-risk) CLL were cocultured in vitro with healthy donor (HD) or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.